New Blood Test Showsโ Promiseโ in Early Bladder Cancer Detection, Boosting Survival Rates
Milan, Italyโ – October 20, 2025 – A novelโ blood test demonstrating high accuracy in โdetecting early-stage bladder cancer is poised to significantly improve patientโค outcomes, offering a less invasive alternative โคto conventional cystoscopies.Researchers at โฃthe European institute of Oncologyโ (IEO) inโค Milan announced today the resultsโ of a multi-center clinical trial revealing the test’s abilityโ to identify theโ disease with up to 85% sensitivity andโ 90% specificity. This breakthrough could dramatically alter the landscape of bladder cancer diagnosis and treatment, possibly leading to earlier interventions and increased survival rates โforโข the approximately 430,000 people diagnosed with theโ disease globally each year.
Bladder cancer, frequently enough initially presenting with subtle symptoms like blood in the โurine, frequentlyโ isn’t โdiagnosed untilโ it has progressed to a โคmore advanced stage. This late detectionโ contributes to a five-year survival rate of approximately 77% in the united States,a figure experts believe โcould be substantially improvedโข with โคearlier diagnosis. Theโ new โblood test analyzes circulating tumor DNA (ctDNA)โ – โfragments of cancer cells’ genetic material released into โthe bloodstream – offering a non-invasive method to identify theโฃ presence of the disease,even before symptoms manifest. The IEO study, published in โ The Lancet oncology, โฃfollowed 500 patients โฃwith suspected โbladder cancer and โ500 healthy controls, demonstrating โthe test’s robust performance across diverse patientโฃ populations. โฃ Researchers anticipate theโ test โwill initiallyโข be used to triage patients, โคreducing the numberโ ofโ needless cystoscopies – a procedureโข frequently enough considered โuncomfortable and requiring specialized equipment – and focusing โฃthem on individuals with a higher probability of having the disease.
